Chest Infections: Tuberculosis |

Trend and Concomitant Drug Resistance of Multidrug-Resistant TB in South Korea FREE TO VIEW

Doosoo Jeon, MD; Hyun Seok Kim, MD; Jeong Ha Mok, MD; Bo Hyoung Kang, MD; Sun Young Kim, MD; Tae Hun Lee, MD; Hyun Kyung Lee, MD; Yu Ji Cho, MD
Author and Funding Information

Pusan National University Yangsan Hospital, Yangsan, Korea (the Republic of)

Copyright 2016, American College of Chest Physicians. All Rights Reserved.

Chest. 2016;150(4_S):202A. doi:10.1016/j.chest.2016.08.211
Text Size: A A A
Published online

SESSION TITLE: Tuberculosis

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM

PURPOSE: This study was conducted to evaluate the recent trend and concomitant drug resistance pattern of multidrug-resistant tuberculosis (MDR-TB) in South Korea.

METHODS: We retrospectively analyzed the results of phenotypic drug susceptibility test of culture confirmed TB patients from 2010 to 2014 in 7 university hospitals in Korea.

RESULTS: In total, 5599 patients were included. MDR-TB accounted for 4.4% (216/4297) among new cases and 24.1% (162/672) among previously treated cases. From 2010 to 2014, proportion of MDR-TB had been gradually decreased among both new and previously treated cases (p<0.001 and p=0.027 for trend, respectively). In 378 patients with MDR-TB, resistance rate of ethambutol and pyrazinamide were high (63.8% and 35.7%, respectively). Resistance rate of any fuloroquinolone and second line injectable drugs were 13.8% and 6.9%, respectively. Resistance rates of group 4 drugs were as follows: para-aminosalicylic acid (31.5%), prothionamide (17.5%) and cycloserine (7.1%). Extensively drug-resistant tuberculosis (XDR TB) (12.4%, n=47) and pre-XDR TB (20.6%, n=78) accounted for 33.0% of MDR-TB.

CONCLUSIONS: Proportion of MDR-TB had been gradually decreased from 2010 to 2014 in Korea. However, concomitant drug resistance rate in MDR-TB were still high.

CLINICAL IMPLICATIONS: When determining the treatment regimens for MDR-TB, high resistance rates and resistance patterns of concomitant drugs should be considered.

DISCLOSURE: The following authors have nothing to disclose: Doosoo Jeon, Hyun Seok Kim, Jeong Ha Mok, Bo Hyoung Kang, Sun Young Kim, Tae Hun Lee, Hyun Kyung Lee, Yu Ji Cho

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543